Document is current
Any future updates will be listed below
-
Authors
Alsaadi, Taoufik https://orcid.org/0000-0002-7513-5706
Kayed, Deeb M.
Al-Madani, Abubaker
Hassan, Ali Mohamed
Krieger, Derk
Riachi, Naji
Sarathchandran, Pournamy
Al-Rukn, Suhail
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 17 November 2023
Accepted: 22 December 2023
First Online: 19 January 2024
Declarations
:
: Abubaker Al-Madani, Derk Krieger, Suhail Al-Rukn, and Ali Mohamed Hassan have received speaker and consultancy fees from Pfizer, Eli Lilly, Novartis, Lundbeck, and Abbvie. Taoufik Alsaadi and Naji Riachi have received research grants, as well as speaker and consultancy fees from Pfizer, Eli Lilly, Novartis, Lundbeck, and Abbvie. Deeb M. Kayed has received honoraria, travel support, speaker fees, and advisory board fees from Abbvie, Eli Lilly, Lundbeck, Novartis, and Pfizer. Pournamy Sarathchandran has no competing interest to declare.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The study received IRB approval from the American Center for Psychiatry and Neurology’s IRB ethical exemption, with the reference ACPN_IRB_0058. All experts were authors in the study.
